CNTB — Connect Biopharma Holdings Limited

Summary of Connect Biopharma Q2 2022 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of June 30, 2022, Connect Biopharma reported cash, cash equivalents, and investments totaling $212.9 million, down from RMB 1,706.9 million at the end of 2021. This decline is attributed to increased R&D and administrative costs.
• R&D Expenses: Increased to $50.8 million from RMB 217.8 million, driven by clinical trial costs for CBP-201 and CBP-307.
• Administrative Expenses: Rose to $10.7 million from RMB 48.0 million, primarily due to higher personnel costs and expenses related to public company infrastructure.
• Net Loss: Totaled $59.8 million, a decrease from RMB 942.5 million in the prior year, largely due to the absence of significant fair value adjustments on preferred stock.

2. Strategic Updates and Business Highlights

• CBP-201 (Atopic Dermatitis): The Phase 2b trial met its primary and key secondary endpoints, with plans to report top-line data from a pivotal trial in China in October 2022. The company aims to initiate a global Phase 3 trial by the end of 2022.
• CBP-307 (Ulcerative Colitis): The drug is positioned as a Phase 3-ready candidate, with a focus on its potential for partnerships due to its favorable clinical profile.
• CBP-174 (Chronic Pruritus): Successfully completed a Phase 1 trial, showing a safe and tolerable profile, with plans for future studies to optimize formulation and explore its efficacy in patients.

3. Forward Guidance and Outlook

• CBP-201: Anticipates filing a BLA in China as early as 2025, contingent on positive results from ongoing trials. Enrollment for the global Phase 3 study is expected to begin by the end of 2022.
• CBP-307: Full enrollment in the Phase 2 trial for ulcerative colitis is expected in the first half of 2023, with results anticipated in the second half of 2023.
• CBP-201 in Asthma: Enrollment completion is expected in the first half of 2023, with results to follow in the second half of 2023.

4. Bad News, Challenges, or Points of Concern

• Increased Costs: Rising R&D and administrative expenses are impacting cash reserves, although the company expects to fund operations through at least 2024.
• Competitive Landscape: The atopic dermatitis market is becoming increasingly crowded, posing challenges for differentiation against established treatments like dupilumab.
• Regulatory Risks: The success of the pivotal trial in China is crucial for future approvals and partnerships, with uncertainties surrounding the regulatory feedback and outcomes.

5. Notable Q&A Insights

• Differentiation in AD: Management acknowledged the crowded market for atopic dermatitis treatments but emphasized potential advantages in efficacy and dosing convenience for CBP-201.
• Partnership Opportunities: Discussions for partnerships regarding CBP-307 are ongoing, with expectations for updates in 2023. The company is open to both regional and global partnership deals.
• Regulatory Interactions: Positive feedback from the China CDE regarding the pivotal trial was noted, with plans for a pre-BLA meeting contingent on successful data outcomes.
• Future Indications: There is potential for CBP-201 to be explored for additional indications beyond atopic dermatitis, including asthma and nasal polyps, although the nasal polyp trial was recently terminated due to operational challenges.

Overall, Connect Biopharma is making significant strides in its clinical programs while navigating financial pressures and a competitive landscape. The upcoming months are critical for advancing its drug candidates and securing partnerships.